Ibritumomab Tiuxetan

Category: Cancer



Ibritumomab Tiuxetan Overview

Ibritumomab tiuxetan (pronounced /brtumomæb takstæn/[1]), sold under the trade name Zevalin, is a monoclonal antibody radioimmunotherapy treatment for non-Hodgkin's lymphoma. The drug uses the monoclonal mouse IgG1 antibody ibritumomab in conjunction with the chelator tiuxetan, to which a radioactive isotope (either yttrium-90 or indium-111) is added. Tiuxetan is a modified version of DTPA whose carbon backbone contains an isothiocyanatobenzyl and a methyl group.&...

Read more Ibritumomab Tiuxetan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ibritumomab_tiuxetan

Recent Ibritumomab Tiuxetan Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Ibritumomab Tiuxetan
  • Injection: 3.2mg/2ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Ibritumomab Tiuxetan or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 30 November 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA